Baxter Healthcare Corporation recalls MYXREDLIN
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- CGMP Deviations
- Products
-
- MYXREDLIN
- Where it was sold
-
US Nationwide; Puerto Rico; and Chile.
Nationwide
- Units affected
- N/A
- About this recall
- MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0126-12.